Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron (GERN) Q2 2020 Earnings Call Transcript | The Motley Fool
02:31am, Saturday, 08'th Aug 2020
GERN earnings call for the period ending June 30, 2020.
Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events
08:05pm, Thursday, 06'th Aug 2020
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call
Geron to Present at the BTIG Virtual Biotechnology Conference
08:45pm, Tuesday, 04'th Aug 2020
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will participate in a fireside cha
Geron to Present at the BTIG Virtual Biotechnology Conference
12:00am, Tuesday, 04'th Aug 2020
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Exe
Geron to Announce Second Quarter Financial Results on August 6, 2020
08:30pm, Thursday, 30'th Jul 2020
Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be ava
Will Geron (GERN) Report Negative Q2 Earnings? What You Should Know
04:33pm, Thursday, 30'th Jul 2020
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Embarking on a Python journey? Then ‘Hands-on Machine Learning’ is a must read
09:00am, Tuesday, 28'th Jul 2020
Writing an all-encompassing book on Python machine learning is difficult, given how expansive the field is. But reviewing one is not an easy feat either, especially when it’s a highly acclaimed titl
Geron Sees Hammer Chart Pattern: Time to Buy?
12:28pm, Monday, 27'th Jul 2020
Geron has been struggling lately, but the selling pressure may be coming to an end soon
Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?
03:30pm, Thursday, 23'rd Jul 2020
Is (GERN) Outperforming Other Medical Stocks This Year?
Geron Corporation: An Iffy Slow Burner
01:50pm, Wednesday, 22'nd Jul 2020
Geron Corporation has been focused on the development and commercialization of first-in-class telomerase-inhibiting cancer drugs for as long as 30 long years, and it is only now that its solitary prod
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12:30pm, Thursday, 16'th Jul 2020
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired empl
Scholar Rock Appoints Tony Kingsley as President and CEO
12:00am, Tuesday, 14'th Jul 2020
Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors p
Polycythemia Vera (PV) Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com
12:00am, Monday, 13'th Jul 2020
The
Geron Co. (NASDAQ:GERN) Given Consensus Recommendation of “Buy” by Brokerages
01:50am, Saturday, 04'th Jul 2020
Shares of Geron Co. (NASDAQ:GERN) have earned an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rate
Geron (NASDAQ:GERN) Cut to “Hold” at ValuEngine
02:22am, Friday, 03'rd Jul 2020
Geron (NASDAQ:GERN) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, ValuEngine reports. GERN has be
